Mon, Jun
60 New Articles

Gessel Advises Bioceltix Shareholders on Public Offering

Gessel Advises Bioceltix Shareholders on Public Offering

  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

Gessel has advised the shareholders of Bioceltix on their recent over PLN 20 million no-prospectus public offering of company shares carried out under an accelerated book-building procedure.

The bookkeeping of the offered shares was performed by Dom Maklerski Navigator. Bioceltix is a Wroclaw-headquartered company that develops therapies in veterinary medicine.

According to Gessel, the public offering was conducted jointly by the six shareholders of the company and included a total of 365,876 shares, admitted to trading on the regulated market of the WSE. The offering was addressed to qualified investors and selected retail investors. The total value of the conducted public offering amounted to over PLN 20 million.

Back in July, Gessel had also advised Bioceltix itself on a non-brokered public offering of shares and the related private placement (as reported by CEE Legal Matters on July 10, 2023). 

The Gessel team included Partner Krzysztof Marczuk and Senior Associate Jakub Rowicki.